- 4/2020-present: Assistant, 1st Medical Oncology Department, HYGEIA Hospital, Athens, Greece
- 1/2017-3/2020: Residency in Medical oncology with medical on-call duties, University Hospital of Heraklion, Greece
- 8/2015-8/2016: Specilaty Training 1/2 Trust hematology with medical on-call duties, Broomfield Hospital NHS Mid Essex
- 09/2014-04/2015: Clinical Fellow in Medical Oncology, NHS Beatson Hospital, Glasgow
- 08/2012 – 08/2014: Internal Medicine Unit – General Hospital of Ksanthi, Greece
- 01/2012-05/2012: Post graduate Scholarship in medical capacity, Oncology Unit- Hygeia Hospital, Athens, Greece
- 12/2010-12/2011: Rural Obligatory position(agrotiko), Kalavrita Hospital
Education Experience
- 04/2011: 23th National conference of General Medicine, Kos Greece
Talk presentantion: The side effects of diphosphonates in the oral cavity
Talk presentantion:Pre-symptomatic control of colon cancer: public opinion
- 17-19/11/2017:9th seminar of Clinical Oncology –Thesaloniki,Greece
Talk presentation: metastatic breast cancer,brca mutation ,different disease ?
- 23-26/11/2017: Conference of clinical and translational oncology
Case presentation: neoadjuvant treatment on rectal cancer
- 14-16/11/2018: Conference of clinical and translational oncology, Heraklion, Crete,Greece
- Talk presentation: Case of a patient with BRCA mutant TNBCTalk presentation: 2 cases of metastatic adenocarcinoma with high PDL1 expression
- 23–29/3/2019: 18th ESO-ESMO Masterclass in Clinical Oncology , Lodgut Sober, Germany,presentation of a case report (breast cancer)
- 2nd School of Clinical Immunology, Heraklion, Crete, 2019, presentation to students and clinicians of a case with thymoma that received pembrolizumab.
- 4/7/2020: American Association of Cancer Research in collaboration with European platform for cancer research, Methods in Clinical Research workshop, selected for talk presentation of the research idea: phase I trial of ribociclib –nivolumab-canakimumab, trial design.
- 11/7/2020: Panhellenic Oncology Conference, talk on: Immunotherapy toxicity management, and its continuation in patients with response